Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
NCT ID: NCT05478707
Last Updated: 2025-12-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
SUSPENDED
Clinical Phase
PHASE2
Total Enrollment
47 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-10-05
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
NCT04575844
Metabolic Syndrome
RECRUITING
PHASE4
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
NCT04133922
Type 1 Diabetes
Insulin Sensitivity/Resistance
WITHDRAWN
EARLY_PHASE1
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
NCT03883412
Type2 Diabetes
RECRUITING
PHASE4
Exercise and GLP-1 RA on Insulin Secretion
NCT04383197
Type 2 Diabetes
UNKNOWN
NA
Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes
NCT03668470
Adult Subjects With Type1Diabetes and Insulin Microsecretion
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, 47 (n=32 needed to complete) adult participants with type 1 diabetes will be randomized (1:1) to 14-weeks of one of 2 interventions: 1) dulaglutide, 2) placebo.
Participants will undergo two study admissions at baseline and 14 weeks. Prior to each admission, participants will wear a continuous glucose monitor (Dexcom G6 Professional) for 10 days to assess glycemic variability (GV). Prior to admissions, they will undergo cardiorespiratory fitness testing. On study admission days, participants will undergo an antecubital vein endothelial cell biopsy prior to commencing vascular testing. From the harvested endothelial cells, the investigators will quantify endothelial cell reactive oxygen species (ROS) and gene expression relevant to insulin-mediated endothelial function. Vascular testing will include contrast enhanced ultrasound of quadriceps muscle to determine microvascular blood volume (MBV). The investigators will also measure brachial artery flow mediated dilation (FMD). Quadriceps skeletal muscle oxygenation (HHb) will also be measured. These vascular and muscle oxygenation measurements will be conducted before and after a 120-minute euglycemic insulin clamp which will measure insulin sensitivity based on glucose infusion rate (GIR).
This randomized, placebo-controlled study will assess whether GLP-1 receptor agonism with dulaglutide or exercise training improves insulin-mediated skeletal muscle microvascular perfusion. The investigators will assess for predictive relationships between microvascular perfusion and cardiorespiratory fitness (VO2max), insulin sensitivity (GIR), endothelial reactive oxygen species (ROS), and glycemic variability (GV).
Participants will undergo two study admissions at baseline and 14 weeks. Prior to each admission, participants will wear a continuous glucose monitor (Dexcom G6 Professional) for 10 days to assess glycemic variability (GV). Prior to admissions, they will undergo cardiorespiratory fitness testing. On study admission days, participants will undergo an antecubital vein endothelial cell biopsy prior to commencing vascular testing. From the harvested endothelial cells, the investigators will quantify endothelial cell reactive oxygen species (ROS) and gene expression relevant to insulin-mediated endothelial function. Vascular testing will include contrast enhanced ultrasound of quadriceps muscle to determine microvascular blood volume (MBV). The investigators will also measure brachial artery flow mediated dilation (FMD). Quadriceps skeletal muscle oxygenation (HHb) will also be measured. These vascular and muscle oxygenation measurements will be conducted before and after a 120-minute euglycemic insulin clamp which will measure insulin sensitivity based on glucose infusion rate (GIR).
This randomized, placebo-controlled study will assess whether GLP-1 receptor agonism with dulaglutide or exercise training improves insulin-mediated skeletal muscle microvascular perfusion. The investigators will assess for predictive relationships between microvascular perfusion and cardiorespiratory fitness (VO2max), insulin sensitivity (GIR), endothelial reactive oxygen species (ROS), and glycemic variability (GV).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetes Mellitus, Type 1
Endothelial Dysfunction
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
TRIPLE
Participants
Caregivers
Outcome Assessors
Participants randomized to dulaglutide or placebo and study personnel who analyze data and instruct patients regarding insulin adjustments will be blinded to treatment allocation.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Saline subcutaneous injection, volume matched to dulaglutide, i.e. 0.5 mL weekly for 14 weeks
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Saline placebo
Dulaglutide
Dulaglutide (0.75 mg/0.5 mL weekly for 2 weeks, then 1.5 mg/0.5 mL weekly for 12 weeks) subcutaneous injection
Group Type
ACTIVE_COMPARATOR
Dulaglutide
Intervention Type
DRUG
GLP1-RA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dulaglutide
GLP1-RA
Intervention Type
DRUG
Placebo
Saline placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of type 1 diabetes, duration \> 5 years
* Age 18-40 years
* HbA1c \< 8.5%
* BMI 19-34.9 kg/m2
* Using insulin for diabetes treatment only (multiple daily injections or insulin pump with or without sensor augmentation)
* On stable regimen of non-diabetic medications for the last 6 months
* All screening labs within normal limits or not clinically significant
* C-peptide \<0.6 ng/ml
* Age 18-40 years
* HbA1c \< 8.5%
* BMI 19-34.9 kg/m2
* Using insulin for diabetes treatment only (multiple daily injections or insulin pump with or without sensor augmentation)
* On stable regimen of non-diabetic medications for the last 6 months
* All screening labs within normal limits or not clinically significant
* C-peptide \<0.6 ng/ml
Exclusion Criteria
* Pregnancy or currently breastfeeding
* Smoking history within 6 months
* History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) as well as clinically significant cardiac arrhythmias or conduction disorders
* Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers).
* Known hypersensitivity to perflutren (contained in Definity© contrast)
* Screening O2 saturation \<90%
* Musculoskeletal condition preventing participation in exercise testing or exercise training
* Acute or unstable disease other than T1D
* Hypoglycemia unawareness (based on Clarke's questionnaire)
* History of gastroparesis, severe gastroesophageal reflux, pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
* Anemia (hemoglobin \<12 g/dL in women, hemoglobin \<13 g/dL in men), eosinophilia (absolute eosinophil count \>500 cells/microliter) leukopenia (total white blood cells \<4,000 cells/microliter)
* Diabetic ketoacidosis (DKA) on presentation to screening visits or study admission days
* Hospital admission for DKA within 1 year
* Smoking history within 6 months
* History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) as well as clinically significant cardiac arrhythmias or conduction disorders
* Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers).
* Known hypersensitivity to perflutren (contained in Definity© contrast)
* Screening O2 saturation \<90%
* Musculoskeletal condition preventing participation in exercise testing or exercise training
* Acute or unstable disease other than T1D
* Hypoglycemia unawareness (based on Clarke's questionnaire)
* History of gastroparesis, severe gastroesophageal reflux, pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
* Anemia (hemoglobin \<12 g/dL in women, hemoglobin \<13 g/dL in men), eosinophilia (absolute eosinophil count \>500 cells/microliter) leukopenia (total white blood cells \<4,000 cells/microliter)
* Diabetic ketoacidosis (DKA) on presentation to screening visits or study admission days
* Hospital admission for DKA within 1 year
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Virginia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kaitlin Love, MD
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kaitlin Love, MD
Role: PRINCIPAL_INVESTIGATOR
Associate Professor - Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia
Charlottesville, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
[Hazards to the conception product of drugs administered to the pregnant woman. I. Round table discussion]. Bull Fed Soc Gynecol Obstet Lang Fr. 1968;20(5):Suppl:288-95. No abstract available. French.
Reference Type
BACKGROUND
Specter SC, Klein TW, Newton C, Mondragon M, Widen R, Friedman H. Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. Int J Immunopharmacol. 1986;8(7):741-5. doi: 10.1016/0192-0561(86)90010-x.
Reference Type
BACKGROUND
Budalica M, Plamenac P, Tvrtkovic R, Gmaz-Nikulin E. [Cystic mediastinal lymphangioma]. Srp Arh Celok Lek. 1971 Jun;99(6):395-401. No abstract available. Serbian.
Reference Type
BACKGROUND
Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep. 1985 Sep;69(9):945-51.
Reference Type
BACKGROUND
Harrison RM. Tissue-air ratios and scatter-air ratios for diagnostic radiology (1-4 mm Al HVL). Phys Med Biol. 1983 Jan;28(1):1-18. doi: 10.1088/0031-9155/28/1/001.
Reference Type
BACKGROUND
Furuyama F. Strain difference in thermoregulation of rats surviving extreme heat. J Appl Physiol Respir Environ Exerc Physiol. 1982 Feb;52(2):410-5. doi: 10.1152/jappl.1982.52.2.410.
Reference Type
BACKGROUND
Tabayashi K, McKeown PP, Miyamoto M, Luedtke AE, Thomas R, Allen MD, Misbach GA, Ivey TD. Ischemic myocardial protection. Comparison of nonoxygenated crystalloid, oxygenated crystalloid, and oxygenated fluorocarbon cardioplegic solutions. J Thorac Cardiovasc Surg. 1988 Feb;95(2):239-46.
Reference Type
BACKGROUND
Donga E, Dekkers OM, Corssmit EP, Romijn JA. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol. 2015 Jul;173(1):101-9. doi: 10.1530/EJE-14-0911. Epub 2015 Apr 21.
Reference Type
BACKGROUND
Kuijpers PJ, Lacquet LK, Skotnicki SH, Linssen GH, Vonk JT. Surgical treatment for acute myocardial ischaemia. J Cardiovasc Surg (Torino). 1974 Mar;15(2):209-10. No abstract available.
Reference Type
BACKGROUND
Xu TH, Xie DZ, Wan TB, Pai B, Wang LX. Studies on immunological changes among schizophrenic patients. Schizophr Res. 1988 Nov-Dec;1(6):431-3. doi: 10.1016/0920-9964(88)90026-6. No abstract available.
Reference Type
BACKGROUND
Poldermans D, Arnese M, Fioretti PM, Salustri A, Boersma E, Thomson IR, Roelandt JR, van Urk H. Improved cardiac risk stratification in major vascular surgery with dobutamine-atropine stress echocardiography. J Am Coll Cardiol. 1995 Sep;26(3):648-53. doi: 10.1016/0735-1097(95)00240-5.
Reference Type
BACKGROUND
Ce GV, Rohde LE, da Silva AM, Punales MK, de Castro AC, Bertoluci MC. Endothelial dysfunction is related to poor glycemic control in adolescents with type 1 diabetes under 5 years of disease: evidence of metabolic memory. J Clin Endocrinol Metab. 2011 May;96(5):1493-9. doi: 10.1210/jc.2010-2363. Epub 2011 Feb 23.
Reference Type
BACKGROUND
Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging. 2010 Aug;26(6):631-40. doi: 10.1007/s10554-010-9616-1. Epub 2010 Mar 26.
Reference Type
BACKGROUND
Mischler TW, Rubio B, Larranaga A, Guiloff E, Moggia AV. Further experience with quingestanol acetate as a postcoital oral contraceptive. Contraception. 1974 Mar;9(3):221-5. doi: 10.1016/0010-7824(74)90013-4.
Reference Type
BACKGROUND
Love KM, Jahn LA, Hartline LM, Patrie JT, Barrett EJ, Liu Z. Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans. Sci Rep. 2021 Jun 1;11(1):11433. doi: 10.1038/s41598-021-90935-8.
Reference Type
BACKGROUND
Bertelli A, Giovannini L, Romano MR, Maltinti G, Dell'Osso L, Bertelli AA. Experimental comparative renal toxicity of lithium and rubidium. Drugs Exp Clin Res. 1985;11(4):269-73.
Reference Type
BACKGROUND
Akber SF. The physics of NMR tomography. Nuklearmedizin. 1986 Feb;25(1):33-8.
Reference Type
BACKGROUND
Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res. 1995 Dec 1;55(23):5693-8.
Reference Type
BACKGROUND
Liu HY, Cao SY, Hong T, Han J, Liu Z, Cao W. Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). J Biol Chem. 2009 Oct 2;284(40):27090-100. doi: 10.1074/jbc.M109.016675. Epub 2009 Aug 4.
Reference Type
BACKGROUND
Wang N, Tan AWK, Jahn LA, Hartline L, Patrie JT, Lin S, Barrett EJ, Aylor KW, Liu Z. Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance. Diabetes Care. 2020 Mar;43(3):634-642. doi: 10.2337/dc19-1465. Epub 2019 Dec 30.
Reference Type
BACKGROUND
Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014 Jan;232(1):156-64. doi: 10.1016/j.atherosclerosis.2013.10.025. Epub 2013 Nov 5.
Reference Type
BACKGROUND
Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, Aylor KW, Basu A, Liu Z. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond). 2014 Aug;127(3):163-70. doi: 10.1042/CS20130708.
Reference Type
BACKGROUND
Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, Fossler M, Davila-Roman VG, Russell SD, Gropler RJ. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2016 Jul;4(7):559-566. doi: 10.1016/j.jchf.2016.01.008. Epub 2016 Mar 30.
Reference Type
BACKGROUND
Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1289-95. doi: 10.1152/ajpendo.00373.2007. Epub 2007 Aug 21.
Reference Type
BACKGROUND
Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, Gnasso A. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res. 2013 Jan;10(1):72-7. doi: 10.1177/1479164112449562. Epub 2012 Jun 25.
Reference Type
BACKGROUND
Kiraly JF, Becker CE, Williams HE. Diabetic ketoacidosis. A review of cases at a university medical center. Calif Med. 1970 Apr;112(4):1-9.
Reference Type
BACKGROUND
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
Reference Type
BACKGROUND
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.
Reference Type
BACKGROUND
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
Reference Type
BACKGROUND
Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992 May 14;326(20):1316-22. doi: 10.1056/NEJM199205143262003.
Reference Type
BACKGROUND
Mochon MC, Leyva JA. A new spectrophotometric method for determining triglycerides in serum. Clin Chim Acta. 1984 Sep 29;142(2):281-5. doi: 10.1016/0009-8981(84)90387-5. No abstract available.
Reference Type
BACKGROUND
Farinha JB, Ramis TR, Vieira AF, Macedo RCO, Rodrigues-Krause J, Boeno FP, Schroeder HT, Muller CH, Boff W, Krause M, De Bittencourt PIH Jr, Reischak-Oliveira A. Glycemic, inflammatory and oxidative stress responses to different high-intensity training protocols in type 1 diabetes: A randomized clinical trial. J Diabetes Complications. 2018 Dec;32(12):1124-1132. doi: 10.1016/j.jdiacomp.2018.09.008. Epub 2018 Sep 19.
Reference Type
BACKGROUND
Tielemans SM, Soedamah-Muthu SS, De Neve M, Toeller M, Chaturvedi N, Fuller JH, Stamatakis E. Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2013 Jan;56(1):82-91. doi: 10.1007/s00125-012-2743-6. Epub 2012 Oct 10.
Reference Type
BACKGROUND
Tikkanen-Dolenc H, Waden J, Forsblom C, Harjutsalo V, Thorn LM, Saraheimo M, Elonen N, Tikkanen HO, Groop PH; FinnDiane Study Group. Physical Activity Reduces Risk of Premature Mortality in Patients With Type 1 Diabetes With and Without Kidney Disease. Diabetes Care. 2017 Dec;40(12):1727-1732. doi: 10.2337/dc17-0615. Epub 2017 Oct 16.
Reference Type
BACKGROUND
Komatsu WR, Gabbay MA, Castro ML, Saraiva GL, Chacra AR, de Barros Neto TL, Dib SA. Aerobic exercise capacity in normal adolescents and those with type 1 diabetes mellitus. Pediatr Diabetes. 2005 Sep;6(3):145-9. doi: 10.1111/j.1399-543X.2005.00120.x.
Reference Type
BACKGROUND
Lespagnol E, Tagougui S, Fernandez BO, Zerimech F, Matran R, Maboudou P, Berthoin S, Descat A, Kim I, Pawlak-Chaouch M, Boissiere J, Boulanger E, Feelisch M, Fontaine P, Heyman E. Circulating biomarkers of nitric oxide bioactivity and impaired muscle vasoreactivity to exercise in adults with uncomplicated type 1 diabetes. Diabetologia. 2021 Feb;64(2):325-338. doi: 10.1007/s00125-020-05329-8. Epub 2020 Nov 21.
Reference Type
BACKGROUND
Turinese I, Marinelli P, Bonini M, Rossetti M, Statuto G, Filardi T, Paris A, Lenzi A, Morano S, Palange P. "Metabolic and cardiovascular response to exercise in patients with type 1 diabetes". J Endocrinol Invest. 2017 Sep;40(9):999-1005. doi: 10.1007/s40618-017-0670-6. Epub 2017 Apr 6.
Reference Type
BACKGROUND
Eckstein ML, Farinha JB, McCarthy O, West DJ, Yardley JE, Bally L, Zueger T, Stettler C, Boff W, Reischak-Oliveira A, Riddell MC, Zaharieva DP, Pieber TR, Muller A, Birnbaumer P, Aziz F, Brugnara L, Haahr H, Zijlstra E, Heise T, Sourij H, Roden M, Hofmann P, Bracken RM, Pesta D, Moser O. Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis. Diabetes Care. 2021 Jan;44(1):240-247. doi: 10.2337/dc20-1496. Epub 2020 Nov 12.
Reference Type
BACKGROUND
Olsen PR, Iversen HG, Hansen RI, Wolf H. [A simple preoperative ultrasonic method of estimating the size of the prostate]. Ugeskr Laeger. 1984 Dec 10;146(50):3899-901. No abstract available. Danish.
Reference Type
BACKGROUND
Schmidtke JR, Dixon FJ. The functional capacity of x-irradiated macrophages. J Immunol. 1972 Jun;108(6):1624-30. No abstract available.
Reference Type
BACKGROUND
Archer-Duste H. Clinical ethics: a mandate for nursing. J Perinat Neonatal Nurs. 1988 Jan;1(3):49-56. doi: 10.1097/00005237-198801000-00007. No abstract available.
Reference Type
BACKGROUND
Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998 Feb 10;97(5):473-83. doi: 10.1161/01.cir.97.5.473.
Reference Type
BACKGROUND
Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes. 2004 Jun;53(6):1418-23. doi: 10.2337/diabetes.53.6.1418.
Reference Type
BACKGROUND
Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42. doi: 10.2337/db05-1373.
Reference Type
BACKGROUND
Greenberg RN, Reilly PM, Weinandt WJ, Wilson KM, Bollinger M, Ojile JM. Comparison trial of clindamycin with aztreonam or gentamicin in the treatment of postpartum endometritis. Clin Ther. 1987;10(1):36-9.
Reference Type
BACKGROUND
Herranz Jordan B, Bermudez-Canete Fernandez R, Herraiz Sarachaga JI, Acerete Guillen F, Bialkowski J, Gonzalez Dieguez C, Sanchez Fernandez PA, Diez Balda JI, Quero Jimenez M. [Non-surgical extraction of intravascular foreign bodies in children. Experience with 8 cases]. Rev Esp Cardiol. 1995 May;48(5):326-32. Spanish.
Reference Type
BACKGROUND
Crisci I, Aragona M, Politi KS, Daniele G, Del Prato S. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol. 2015 Dec;52(6):1129-33. doi: 10.1007/s00592-015-0800-6. Epub 2015 Aug 21.
Reference Type
BACKGROUND
Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016 Oct;39(10):1702-10. doi: 10.2337/dc16-0691. Epub 2016 Aug 9.
Reference Type
BACKGROUND
Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB; ADJUNCT TWO Investigators. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care. 2016 Oct;39(10):1693-701. doi: 10.2337/dc16-0690. Epub 2016 Aug 4.
Reference Type
BACKGROUND
Scott SN, Cocks M, Andrews RC, Narendran P, Purewal TS, Cuthbertson DJ, Wagenmakers AJM, Shepherd SO. High-Intensity Interval Training Improves Aerobic Capacity Without a Detrimental Decline in Blood Glucose in People With Type 1 Diabetes. J Clin Endocrinol Metab. 2019 Feb 1;104(2):604-612. doi: 10.1210/jc.2018-01309.
Reference Type
BACKGROUND
Lim F, Yang CZ, Cooper SL. Synthesis, characterization and ex vivo evaluation of polydimethylsiloxane polyurea-urethanes. Biomaterials. 1994 May;15(6):408-16. doi: 10.1016/0142-9612(94)90218-6.
Reference Type
BACKGROUND
Easty GC, Easty DM, Tchao R. The growth of heterologous tumour cells in chick embryos. Eur J Cancer (1965). 1969 Jun;5(3):287-95. doi: 10.1016/0014-2964(69)90079-6. No abstract available.
Reference Type
BACKGROUND
Jordan EM, Breen GA. Upstream region of a nuclear gene encoding the alpha-subunit of the human mitochondrial F0F1 ATP synthase. Biochim Biophys Acta. 1993 Apr 29;1173(1):115-7. doi: 10.1016/0167-4781(93)90256-d.
Reference Type
BACKGROUND
Travers GR, Ammon RG. The sodium hydroxide chemical matricectomy procedure. J Am Podiatry Assoc. 1980 Sep;70(9):476-8. doi: 10.7547/87507315-70-9-476. No abstract available.
Reference Type
BACKGROUND
Bally L, Zueger T, Buehler T, Dokumaci AS, Speck C, Pasi N, Ciller C, Paganini D, Feller K, Loher H, Rosset R, Wilhelm M, Tappy L, Boesch C, Stettler C. Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study. Diabetologia. 2016 Apr;59(4):776-84. doi: 10.1007/s00125-015-3854-7. Epub 2016 Jan 6.
Reference Type
BACKGROUND
Martins EM, dos Santos RR, Moraes WB. [Biochemical aspects of resistance mechamism of mango (mangifera indica l. to ceratocystis fimbriata ell. & hals]. Arq Inst Biol (Sao Paulo). 1974 Oct-Dec;41(4):175-83. No abstract available. Portuguese.
Reference Type
BACKGROUND
Colombo PC, Ashton AW, Celaj S, Talreja A, Banchs JE, Dubois NB, Marinaccio M, Malla S, Lachmann J, Ware JA, Le Jemtel TH. Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium. J Appl Physiol (1985). 2002 Mar;92(3):1331-8. doi: 10.1152/japplphysiol.00680.2001.
Reference Type
BACKGROUND
Fox E, Abbatte EA, Said-Salah, Constantine NT, Wassef HH, Woody JN. Viral hepatitis markers in Djibouti: an epidemiological survey. Trans R Soc Trop Med Hyg. 1988;82(5):750-2. doi: 10.1016/0035-9203(88)90225-8.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
210198
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes
NCT02127047
COMPLETED
PHASE2
Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
NCT02655770
COMPLETED
PHASE4
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
NCT02882737
COMPLETED
NA
Hyperinsulinemic Euglycemic Clamp Protocol
NCT01408667
COMPLETED
PHASE1/PHASE2
Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults
NCT04730882
COMPLETED
A Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes
NCT04118374
COMPLETED
NA
Glucagon Counterregulation in Type 1 Diabetes
NCT03547427
TERMINATED
NA
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
NCT02777073
COMPLETED
NA
Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes
NCT04374578
COMPLETED
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
NCT04387201
COMPLETED
PHASE4
Glucagon-like Peptide-1 in Type 1 Diabetes
NCT04355832
WITHDRAWN
EARLY_PHASE1
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants
NCT01436201
COMPLETED
PHASE1
Effects of GRA in Patients With Type 1
NCT04779645
ACTIVE_NOT_RECRUITING
PHASE2
Liraglutide in Type 1 Diabetes
NCT01722240
COMPLETED
PHASE3
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
NCT01931982
COMPLETED
PHASE4
Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options
NCT02365740
UNKNOWN
NA
Glucose Variability in Subclinical Hypertrophy
NCT02748434
ACTIVE_NOT_RECRUITING
NA
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
NCT01455441
COMPLETED
PHASE4
Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus
NCT06057077
UNKNOWN
PHASE1/PHASE2
A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants
NCT01432938
COMPLETED
PHASE1
Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1
NCT01347801
COMPLETED
NA
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
NCT03426085
UNKNOWN
PHASE2
Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure
NCT00264199
COMPLETED
NA
GLP-1 and Hypoglycemia
NCT01858896
ACTIVE_NOT_RECRUITING
EARLY_PHASE1